Emerging evidence indicates JAK inhibitors could be a valuable alternative for managing checkpoint inhibitor–induced immune ...

Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. This post hoc analysis evaluated patients receiving tofacitinib monotherapy or combination therapy, ...

Objective To compare the relationship between clinical measures and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with tofacitinib or methotrexate (MTX).Methods ...

The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, Fresenius Kabi, Hexal, Eli Lilly, Pfizer, Samsung Bioepis, Sanofi Aventis, ...

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

In recent years, JAK inhibitors have been developed for the treatment of various inflammatory and autoimmune diseases. This class of inhibitors comprises more than a dozen drugs, including tofacitinib ...

Tofacitinib treatment leads to improved disease control and physical function among patients with juvenile idiopathic arthritis (JIA), with higher rates of clinically inactive disease and remission ...

Patients with axSpA who received UPA reported rapid and sustained improvements in total and nocturnal back pain over 12 weeks.

Upadacitinib was associated with the highest crude prevalence of acne (15.9%), followed by tofacitinib (4.3%) and filgotinib (1.9%). A dose-response relationship was identified for upadacitinib and ...

At 52 weeks, 20.6% of the upadacitinib group and 37.5% of the mycophenolate group had ≥ 5% absolute decline from baseline in FVC. A 10% drop in FVC from baseline at 1 year was also more common ...

Treatment with upadacitinib (UPA) leads to early and sustained reductions in spinal pain and other pain-related symptoms among individuals with axial spondyloarthritis (axSpA), according to study ...